Patents by Inventor Ira D. Goldfine
Ira D. Goldfine has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090280112Abstract: Disclosed herein are methods and compositions for the treatment of prostate cancer with an IGF-1 receptor kinase inhibitor. Methods are also provided for the treatment of prostate cancer by identifying a level of IGF-1 receptor expression and making a decision whether to treat with an IGF-1 receptor kinase inhibitor.Type: ApplicationFiled: May 1, 2009Publication date: November 12, 2009Inventors: IRA D. Goldfine, Jack F. Youngren, Michael J. Campbell, Betty A. Maddux, John A. Kerner, Charles J. Ryan
-
Patent number: 6831070Abstract: The present invention provides methods of delivering a secreted protein into the bloodstream of a mammal. A nucleic acid molecule encoding the protein is introduced into the gastrointestinal tract of the mammal, and the nucleic acid molecule enters an intestinal epithelial cell, where the protein is produced and secreted into the bloodstream of the mammal.Type: GrantFiled: March 16, 2001Date of Patent: December 14, 2004Assignee: Regents of the University of CaliforniaInventors: Michael German, Ira D. Goldfine, Stephen S. Rothman
-
Publication number: 20040127448Abstract: The invention features methods for delivering a polypeptide to the bloodstream of a subject by introduction of a nucleic acid construct into secretory gland cells (e.g., cells of salivary gland, pancreas, or liver). In general, the method involves introduction of a nucleic acid construct into a secretory gland duct, which introduction results in expression of a gene product encoded by the introduced construct and delivery of the gene product into the bloodstream of the subject.Type: ApplicationFiled: December 11, 2003Publication date: July 1, 2004Applicant: The Regents of The University of CaliforniaInventors: Michael S. German, Ira D. Goldfine, Stephen S. Rothman
-
Patent number: 6566342Abstract: Secretory gland cells, particularly pancreatic and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: GrantFiled: January 4, 2001Date of Patent: May 20, 2003Assignee: The Regents of the University of CaliforniaInventors: Michael German, Ira D. Goldfine, Stephen S. Rothman
-
Publication number: 20030078226Abstract: The invention features methods for delivering a polypeptide to the bloodstream of a subject by introduction of a nucleic acid construct into secretory gland cells(e.g., cells of salivary gland, pancreas, or liver). In general, the method involves introduction of a nucleic acid construct into a secretory gland duct, which introduction results in expression of a gene product encoded by the introduced construct and delivery of the gene product into the bloodstream of the subject.Type: ApplicationFiled: June 14, 2002Publication date: April 24, 2003Inventors: Michael S. German, Ira D. Goldfine, Stephen S. Rothman
-
Patent number: 6531455Abstract: The invention features methods for delivering a polypeptide to the bloodstream of a subject by introduction of a nucleic acid construct into secretory gland cells(e.g., cells of salivary gland, pancreas, or liver). In general, the method involves introduction of a nucleic acid construct into a secretory gland duct, which introduction results in expression of a gene product encoded by the introduced construct and delivery of the gene product into the bloodstream of the subject.Type: GrantFiled: April 14, 2000Date of Patent: March 11, 2003Assignee: The Regents of the University of CaliforniaInventors: Michael S. German, Ira D. Goldfine, Stephen S. Rothman
-
Publication number: 20020193337Abstract: Secretory gland cells, particularly pancreatic and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: ApplicationFiled: June 14, 2002Publication date: December 19, 2002Inventors: Michael German, Ira D. Goldfine, Stephen S. Rothman
-
Publication number: 20020039574Abstract: The present invention provides methods of delivering a secreted protein into the bloodstream of a mammal. A nucleic acid molecule encoding the protein is introduced into the gastrointestinal tract of the mammal, and the nucleic acid molecule enters an intestinal epithelial cell, where the protein is produced and secreted into the bloodstream of the mammal.Type: ApplicationFiled: March 16, 2001Publication date: April 4, 2002Inventors: Michael German, Ira D. Goldfine, Stephen S. Rothman
-
Publication number: 20010036925Abstract: Secretory gland cells, particularly pancreatic and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: ApplicationFiled: January 4, 2001Publication date: November 1, 2001Inventors: Michael German, Ira D. Goldfine, Stephen S. Rothman
-
Patent number: 6258789Abstract: Intestinal epithelial cells of a mammalian subject are genetically altered to operatively incorporate a gene which expresses a protein which has a desired effect. The method of the invention comprises administration of a formulation containing DNA to the gastrointestinal tract, preferably by an oral route. The expressed recombinant protein is secreted directly into the bloodstream. Of particular interest is the use of the method of the invention to provide for short term delivery of gene products to the bloodstream.Type: GrantFiled: June 11, 1999Date of Patent: July 10, 2001Assignee: The Regents of the University of CaliforniaInventors: Michael German, Ira D. Goldfine, Stephen S. Rothman
-
Patent number: 6255289Abstract: Secretory gland cells, particularly pancreatic and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: GrantFiled: August 7, 1998Date of Patent: July 3, 2001Assignee: The Regents of the University of CaliforniaInventors: Michael German, Ira D. Goldfine, Stephen S. Rothman
-
Patent number: 6225290Abstract: Intestinal epithelial cells of a mammalian subject are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect. Intestinal cell transformation is accomplished by administration of a formulation composed primarily of naked DNA, and is preferably administered orally. Oral or other intragastrointestinal routes of administration provide a simple method of administration, while the use of naked nucleic acid avoids the complications associated with use of viral vectors to accomplish gene therapy. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed intestinal epithelial cells provide short or long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: GrantFiled: September 19, 1996Date of Patent: May 1, 2001Assignee: The Regents of the University of CaliforniaInventors: Michael German, Ira D. Goldfine, Stephen S. Rothman
-
Patent number: 6004944Abstract: Secretory gland cells, particularly pancreatic, hepatic, and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the bloodstream to obtain therapeutic levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term or short term therapies for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: GrantFiled: October 2, 1997Date of Patent: December 21, 1999Assignee: The Regents of the University of CaliforniaInventors: Stephen S. Rothman, Ira D. Goldfine, Michael S. German
-
Patent number: 5968508Abstract: A method of diagnosing insulin resistance and related disorders is provided. Additionally, methods of treating mammals with insulin resistance and related disorders is provided. The methods employ antagonists to an insulin receptor tyrosine kinase inhibitor protein.Type: GrantFiled: July 19, 1995Date of Patent: October 19, 1999Assignee: Regents of the University of California, TheInventors: Ira D. Goldfine, Andrew Grupe, Betty A. Maddux, Steven Spencer, Timothy A. Stewart, Denise M. Harrison
-
Patent number: 5939269Abstract: A method of diagnosing insulin resistance and related disorders is provided. Additionally, methods of treating animals with insulin resistance and related disorders if provided. The methods employ antagonists to an insulin receptor tyrosine kinase inhibitor protein.Type: GrantFiled: March 2, 1995Date of Patent: August 17, 1999Assignees: The Regents Of The University Of California, Genentech, Inc.Inventors: Ira D. Goldfine, Andrew Grupe, Betty A. Maddux, Steven Spencer, Timothy A. Stewart
-
Patent number: 5885971Abstract: Secretory gland cells, particularly pancreatic and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: GrantFiled: January 16, 1996Date of Patent: March 23, 1999Assignee: The Regents of the University of CaliforniaInventors: Michael German, Ira D. Goldfine, Stephen S. Rothman
-
Patent number: 5837693Abstract: Secretory gland cells, particularly pancreatic and salivary gland cells, are genetically altered to operatively incorporate a gene which expresses a protein which has a desired therapeutic effect on a mammalian subject. The expressed protein is secreted directly into the gastrointestinal tract and/or blood stream to obtain therapeutic blood levels of the protein thereby treating the patient in need of the protein. The transformed secretory gland cells provide long term therapeutic cures for diseases associated with a deficiency in a particular protein or which are amenable to treatment by overexpression of a protein.Type: GrantFiled: March 24, 1995Date of Patent: November 17, 1998Assignee: The Regents of the University of CaliforniaInventors: Michael German, Ira D. Goldfine, Stephen S. Rothman